Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial
SQ3370, the first demonstration of click chemistry within the human body in a clinical setting, facilitated the delivery of chemotherapy to tumors and unlocked additional biological effects such as favorable immune responses that may benefit patients with metastasis. Consistent safety, toxicology, pharmacokinetic, and immune activation results observed across species highlight the translatability of the technology and position click chemistry as a powerful new modality for the development of targeted cancer therapeutics.
Authors
- Amir Mahmoodi (ORCID: https://orcid.org/0000-0002-2924-2957)
- Alexander Guminski (ORCID: https://orcid.org/0000-0003-3681-7015)
- José M. Mejía Oneto (ORCID: https://orcid.org/0000-0001-9384-9430)
- Maša Alečković (ORCID: https://orcid.org/0000-0001-5653-8502)
- Tri‐Hung Nguyen (ORCID: https://orcid.org/0000-0001-6976-4082)
- Sant P. Chawla (ORCID: https://orcid.org/0000-0002-9522-6744)
- Michael Zakharian
- Sangeetha Srinivasan (ORCID: https://orcid.org/0000-0002-4065-1479)
- Nathan K. Yee (ORCID: https://orcid.org/0000-0003-1188-6313)
- Stefanie Wagner
Institutions
- The University of Sydney (AU)
- Royal North Shore Hospital (AU)
- Cooperative Trials Group for Neuro-Oncology (AU)
- Sarcoma Oncology Center (US)
- IQ Samhällsbyggnad (SE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2539
- Citations
- 1
- Primary Topic
- Click Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Institutes of Health
- Knight Cancer Institute, Oregon Health and Science University
- National Cancer Institute